Stocktoria
Altimmune, Inc. ALT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2005-10-06
Altimmune, Inc. statistics & valuation
Market cap$548.4M
P / B2.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -230461.0% | -515860.0% | -22518.5% | 129029.4% | -2197.4% |
| Net margin | -214861.0% | -475295.0% | -20762.2% | 124577.9% | -2201.4% |
| FCF margin | -164746.3% | — | -17806.8% | 92223.5% | -2048.7% |
| Return on assets | -31.5% | -68.2% | -42.0% | -40.9% | -44.4% |
| Return on equity | -39.2% | -77.0% | -45.6% | -45.7% | -48.8% |
| Debt / equity | 0.15× | — | — | 0.02× | 0.01× |
| Current ratio | 18.55 | 13.11 | 17.26 | 11.31 | 11.17 |
| Revenue growth | 105.0% | -95.3% | -726.5% | -101.5% | -46.1% |
Source: SEC EDGAR filings · CIK 0001326190 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.